596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab

Rachel Sanborn; Nashat Gabrail; Benedito Carneiro; Mark O'Hara; Rodolfo Bordoni; Michael Gordon; Danny Khalil; Ralph Hauke; Cherie Taglienti; Mark Rogalski; Rachel Styles; Diego Alvarado; Deena Maurer; Linda Crew; Tibor Keler; Michael Yellin

doi:10.1136/jitc-2022-SITC2022.0596

Article info

Regular and Young Investigator Award Abstracts

Clinical Trials Completed

596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab

Free

Authors

Rachel Sanborn Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States PubMed articles Google scholar articles
Nashat Gabrail Gabrail Cancer Center, Canton, OH, United States PubMed articles Google scholar articles
Benedito Carneiro Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, United States PubMed articles Google scholar articles
Mark O'Hara Hospital of the University of Pennsylvania, Philadelphia, PA, United States PubMed articles Google scholar articles
Rodolfo Bordoni Georgia Cancer Specialists, Marietta, GA, United States PubMed articles Google scholar articles
Michael Gordon HonorHealth Research Institute, Scottsdale, AZ, United States PubMed articles Google scholar articles
Danny Khalil Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articles Google scholar articles
Ralph Hauke Nebraska Cancer Specialists, Omaha, NE, United States PubMed articles Google scholar articles
Cherie Taglienti Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Mark Rogalski Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Rachel Styles Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Diego Alvarado Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Deena Maurer Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Linda Crew Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Tibor Keler Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles
Michael Yellin Celldex Therapeutics, Inc., Hampton, NJ, United States PubMed articles Google scholar articles

Citation

Sanborn R, Gabrail N, Carneiro B, et al

596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0596

Publication history

First published November 7, 2022.

Online issue publication

November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password